February 14, 2017
- Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
August 8, 2016
- Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
June 23, 2016
- Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
July 15, 2015
- Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board
February 10, 2015
- Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
December 2, 2014
- Apellis Pharmaceuticals Raises $33M to Fund its Complement Immunotherapy Programs
November 20, 2014
- Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals.
Displaying 81 - 87 of 87 results
